Genentech announced on December 6 that the FDA approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) and chemotherapy (paclitaxel and carboplatin) for first-line treatment of metastatic non-squamous non-small cell lung cancer without EGFR or ALK mutations. . The approval is based on data from a multicenter, open-label, randomized, controlled… Continue Reading Roche PD-L1 first-line therapy for lung cancer

The appearance of PD-1/L1 inhibitors about five or six years ago has triggered a frantic fever in the field of cancer treatment. This class of drugs can use the immune system to fight cancer by relieving the tumor’s suppression of the human immune system. For a small percentage of patients,… Continue Reading The path to tumor immunocombination therapy

This is a picture of a study published online on July 12th in the JAMA Journal of Dermatology (doi:10.1001/jamadermatol. 2017.2106). It is an old photograph of a lung cancer patient receiving PD-1 medication. Follow-up photos of the comparison chart. Dr. Noelia Rivera from the Autonomous University of Barcelona in Spain… Continue Reading PD-1 Makes a Miracle to Turn Black Hair from Lung Cancer Patients